Nymox Pharmaceutical Corporation develops prostate-disease treatments centered on NYMOZARFEX, also described as fexapotide, for benign prostatic hyperplasia and low-grade localized prostate cancer. Company updates commonly address clinical follow-up data, marketing-authorization work, regulatory correspondence, and the product's use as an in-office procedure without anesthesia or analgesia.
Nymox news also covers public-company status and governance matters, including OTCQB trading under NYMXF, annual-report timing, board changes, executive share purchases, and litigation developments involving former personnel or shareholder-related claims. These releases frame the company as a foreign pharmaceutical issuer focused on prostate-treatment commercialization and related corporate controls.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.